Peakstone Realty Trust Valuation
Is T8CA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of T8CA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: T8CA (€12.5) is trading below our estimate of fair value (€21.78)
Significantly Below Fair Value: T8CA is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for T8CA?
Other financial metrics that can be useful for relative valuation.
| What is T8CA's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$515.44m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.1x |
| Enterprise Value/EBITDA | 15.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does T8CA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.2x | ||
AOX alstria office REIT-AG | 4.5x | -1.8% | €1.1b |
HABA Hamborner REIT | 5.1x | 1.1% | €537.7m |
CMW Cromwell Property Group | 5.2x | 6.3% | AU$1.2b |
ABG Abacus Group | 5.8x | 1.2% | AU$1.1b |
T8CA Peakstone Realty Trust | 2.3x | 4.7% | €515.4m |
Price-To-Sales vs Peers: T8CA is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (5.2x).
Price to Earnings Ratio vs Industry
How does T8CA's PE Ratio compare vs other companies in the European Office REITs Industry?
Price-To-Sales vs Industry: T8CA is good value based on its Price-To-Sales Ratio (2.3x) compared to the European Office REITs industry average (8.7x).
Price to Sales Ratio vs Fair Ratio
What is T8CA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.3x |
| Fair PS Ratio | 3.2x |
Price-To-Sales vs Fair Ratio: T8CA is good value based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €12.50 | €11.21 -10.3% | 4.0% | €11.66 | €10.76 | n/a | 2 |
| Sep ’25 | €11.90 | €11.21 -5.8% | 4.0% | €11.66 | €10.76 | n/a | 2 |
| Aug ’25 | €11.50 | €12.98 +12.9% | 14.3% | €14.83 | €11.12 | n/a | 2 |
| Jul ’25 | €10.00 | €12.98 +29.8% | 14.3% | €14.83 | €11.12 | n/a | 2 |
| Jun ’25 | €11.30 | €12.98 +14.8% | 14.3% | €14.83 | €11.12 | n/a | 2 |
| May ’25 | €13.10 | €12.70 -3.0% | 11.1% | €14.12 | €11.29 | n/a | 2 |
| Apr ’25 | €14.74 | €13.27 -10.0% | 17.2% | €15.56 | €10.98 | n/a | 2 |
| Mar ’25 | €12.45 | €13.11 +5.3% | 19.3% | €15.64 | €10.58 | n/a | 2 |
| Feb ’25 | €13.50 | €13.11 -2.9% | 19.3% | €15.64 | €10.58 | n/a | 2 |
| Jan ’25 | €18.72 | €13.99 -25.3% | 24.6% | €17.43 | €10.55 | n/a | 2 |
| Dec ’24 | €15.53 | €14.60 -6.0% | 37.5% | €20.08 | €9.13 | n/a | 2 |
| Nov ’24 | €11.88 | €16.03 +34.9% | 29.4% | €20.75 | €11.32 | n/a | 2 |
| Oct ’24 | €15.58 | €18.62 +19.5% | 8.6% | €20.23 | €17.01 | n/a | 2 |
| Sep ’24 | €18.33 | €18.62 +1.6% | 8.6% | €20.23 | €17.01 | €11.90 | 2 |
| Aug ’24 | €20.78 | €20.67 -0.5% | 4.3% | €21.57 | €19.78 | €11.50 | 2 |
| Jul ’24 | €25.44 | €23.62 -7.2% | 5.9% | €25.01 | €22.23 | €10.00 | 2 |
Analyst Forecast: Target price is lower than the current share price.